CONTRIBUTI SCIENTIFICI – Scientific Papers
Volume:
Biochimica Clinica 2018; 42(3) 217-224
Pubblicato on-line:
July 18, 2018
DOI:
10.19186/BC_2018.042
Determinazione del perampanel plasmatico: confronto e cross-validazione tra due metodi in cromatografia liquida ad elevate prestazioni con rivelatore spettrofluorimetrico e con rivelatore a spettrometria di massa
AUTORI
1Laboratorio di Patologia Clinica e Genetica Medica, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italia
2Laboratorio di Neurobiologia, Ospedale S. Bortolo, Vicenza, Italia
3Centro Epilessia, Ospedale S. Bortolo, Vicenza, Italia
ABSTRACT
Determination of perampanel in plasma samples: comparison and cross-validation between two HPLC methods utilizing two different detectors: spectrofluorimetric and mass spectrometry
Determination of perampanel in plasma samples: comparison and cross-validation between two HPLC methods utilizing two different detectors: spectrofluorimetric and mass spectrometry. Perampanel (PMP) (2[2-oxo-1-phenyl-5-pyridin-2-y1-1,2 dihydropyridin-3-y1] benzonitrile hydrate) is a novel non-competitive selective antagonist of the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor. In this study, we compared two different methods for the quantification of perampanel in human plasma: a commercially available HPLC kit with fluorescent detector and a kit for determination of 18 different antiepileptic drugs (perampanel excluded) based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) used to implement the perampanel determination. LC-MS/MS method was fully validated according to available guidelines: calibration curves were linear across perampanel concentration range of 2,5-2,800 ng/mL with correlation coefficient >0,99. Accuracy and precision results were in accordance with acceptance criteria (±15%). Data collected from 95 patients, treated with perampanel as maintenance antiepileptic therapy, show a very strong correlation between the two methods. Perampanel plasma concentrations in patient samples at steady state, determined with the LC-MS/MS method, ranged from 35 to 985 ng/mL and are in line with previously reported data.
